DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 204096/S007

SUPPLEMENT APPROVAL

Astellas Pharma US, Inc.
Attention: Mary Jo Pritza, MPH, PharmD
Senior Director, Regulatory Affairs
1 Astellas Way
Northbrook, Illinois 60062

Dear Dr. Pritza:

Please refer to your Supplemental New Drug Application (sNDA) received December 14, 2018, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA or the Act) for the following:

NDA/Supplement No.	Product Name	Dosage Form/Strength	Date of Submission and Receipt
204096/S007	Astagraf XL® (tacrolimus extended-release capsules)	Capsules, 0.5 mg, 1 mg, and 5 mg	December 14, 2018

This Prior Approval supplemental new drug application provides for the following revisions to the Prescribing Information:

- Section 6.2 Postmarketing Adverse Reactions to add febrile neutropenia to Hemic/Lymphatic subsection and optic neuropathy to the Special Senses subsection
- Section 7 Drug Interactions, Table 15 to add letermovir to the list of agents which may increase tacrolimus whole blood trough concentrations.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text, which is identical to the labeling submitted on May 21, 2019, and with the following minor editorial changes:

- In the Highlights of Prescribing Information, under the section Warnings and Precaution, the heading "New Onset Diabetes After Transplant" has been underlined.
- In the Highlights of Prescribing Information, the revision date was updated to "6/2019".

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Wendy Streight, PhD, Regulatory Project Manager, at (301) 796-1600.

Sincerely,

{See appended electronic signature page}

Ozlem Belen, MD
Acting Director
Division of Transplant and Ophthalmology Products
Office of Antimicrobial products
Center for Drug Evaluation and Research

ENCLOSURES:
Content of Labeling: Prescribing Information and Medication Guide

---

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

OZLEM A BELEN
06/11/2019 05:30:45 PM